Published in Clinical Oncology Week, May 30th, 2005
Neuro-oncologists in the United States conducted a study "to determine the median survival time of adults with supratentorial glioblastoma treated with a combination" of TMZ and cRA "given daily with conventional radiation therapy (XRT)."
"This was a single arm, open-labeled, Phase II study," explained N. Butowski and coauthors at the University of California-San Francisco. "Patients were treated with XRT in conjunction with cRA and TMZ."
"Both drugs were administered starting on Day 1 of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.